579 related articles for article (PubMed ID: 31936237)
1. Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer.
Chang CW; Lee HC; Li LH; Chiang Chiau JS; Wang TE; Chuang WH; Chen MJ; Wang HY; Shih SC; Liu CY; Tsai TH; Chen YJ
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936237
[TBL] [Abstract][Full Text] [Related]
2.
Chang CW; Liu CY; Lee HC; Huang YH; Li LH; Chiau JC; Wang TE; Chu CH; Shih SC; Tsai TH; Chen YJ
Front Microbiol; 2018; 9():983. PubMed ID: 29867884
[TBL] [Abstract][Full Text] [Related]
3. Berberine regulates fecal metabolites to ameliorate 5-fluorouracil induced intestinal mucositis through modulating gut microbiota.
Chen H; Zhang F; Li R; Liu Y; Wang X; Zhang X; Xu C; Li Y; Guo Y; Yao Q
Biomed Pharmacother; 2020 Apr; 124():109829. PubMed ID: 31958765
[TBL] [Abstract][Full Text] [Related]
4. Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles in 5-Fluorouracil Induced Intestinal Mucositis.
Li HL; Lu L; Wang XS; Qin LY; Wang P; Qiu SP; Wu H; Huang F; Zhang BB; Shi HL; Wu XJ
Front Cell Infect Microbiol; 2017; 7():455. PubMed ID: 29124041
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic Drugs Induce Different Gut Microbiota Disorder Pattern and NOD/RIP2/NF-κB Signaling Pathway Activation That Lead to Different Degrees of Intestinal Injury.
Huang B; Gui M; Ni Z; He Y; Zhao J; Peng J; Lin J
Microbiol Spectr; 2022 Dec; 10(6):e0167722. PubMed ID: 36222691
[TBL] [Abstract][Full Text] [Related]
7. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
[TBL] [Abstract][Full Text] [Related]
8. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy.
James MI; Iwuji C; Irving G; Karmokar A; Higgins JA; Griffin-Teal N; Thomas A; Greaves P; Cai H; Patel SR; Morgan B; Dennison A; Metcalfe M; Garcea G; Lloyd DM; Berry DP; Steward WP; Howells LM; Brown K
Cancer Lett; 2015 Aug; 364(2):135-41. PubMed ID: 25979230
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M
Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489
[TBL] [Abstract][Full Text] [Related]
10. Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment.
Secombe KR; Crame EE; Tam JSY; Wardill HR; Gibson RJ; Coller JK; Bowen JM
Cancer Chemother Pharmacol; 2022 Feb; 89(2):275-281. PubMed ID: 34854953
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Kuo T; Cho CD; Halsey J; Wakelee HA; Advani RH; Ford JM; Fisher GA; Sikic BI
J Clin Oncol; 2005 Aug; 23(24):5613-9. PubMed ID: 16110021
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
[TBL] [Abstract][Full Text] [Related]
13. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
Uncu D; Aksoy S; Çetin B; Yetişyiğit T; Özdemir N; Berk V; Dane F; Inal A; Harputluoğlu H; Budakoğlu B; Koca D; Sevinç A; Cihan S; Durnalı AG; Özkan M; Öztürk MA; Işıkdoğan A; Büyükberber S; Benekli M; Köş T; Alkış N; Karaca H; Turhal NS; Zengin N;
Oncology; 2013; 84(4):240-5. PubMed ID: 23392240
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
Angitapalli R; Litwin AM; Kumar PR; Nasser E; Lombardo J; Mashtare T; Wilding GE; Fakih MG
Oncology; 2009; 76(5):363-8. PubMed ID: 19321964
[TBL] [Abstract][Full Text] [Related]
16. [Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin].
Park S; Jung JJ; Kim GB; Yoon HS; Ko SH; Ko JE; Lee YS
Korean J Gastroenterol; 2010 May; 55(5):340-3. PubMed ID: 20697195
[TBL] [Abstract][Full Text] [Related]
17. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
18. Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.
Strauss LG; Hoffend J; Koczan D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1226-34. PubMed ID: 19280186
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
[TBL] [Abstract][Full Text] [Related]
20. Carboxymethyl pachyman (CMP) reduces intestinal mucositis and regulates the intestinal microflora in 5-fluorouracil-treated CT26 tumour-bearing mice.
Wang C; Yang S; Gao L; Wang L; Cao L
Food Funct; 2018 May; 9(5):2695-2704. PubMed ID: 29756138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
